HK inno.N

KOSDAQ-195940
KOSDAQ
Pharmaceutical Preparations
Global Rank
#10199
Country Rank
#231
Market Cap
873.58 M
Price
31.09
Change (%)
0.82%
Volume
65,060

HK inno.N's latest marketcap:

873.58 M

As of 06/18/2025, HK inno.N's market capitalization has reached $873.58 M. According to our data, HK inno.N is the 10199th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 873.58 M
Revenue (ttm) 607.05 M
Net Income (ttm) 30 M
Shares Out 28.33 M
EPS (ttm) 1.05
Forward PE 15.74
Ex-Dividend Date 03/28/2025
Earnings Date 07/28/2025
Market Cap Chart
Data Updated: 06/18/2025

HK inno.N's yearly market capitalization.

HK inno.N has seen its market value drop from ₩1.52 T to ₩873.58 M since 2021, representing a total decrease of 99.94% and an annual compound decline rate (CAGR) of 88.38%.
Date Market Cap Change (%) Global Rank
06/18/2025 ₩873.58 M 18.97% 10199
12/30/2024 ₩1.02 T -19.35% 10994
12/28/2023 ₩1.26 T 19.97% 8824
12/29/2022 ₩1.05 T -30.83% 9278
12/30/2021 ₩1.52 T 8069

Company Profile

About HK inno.N Corporation

HK inno.N Corporation is a South Korean pharmaceutical company specializing in the development and distribution of prescription drugs, health products, and beauty solutions. Founded in 1984, the company is headquartered in Cheongju-si, South Korea, and serves markets globally, including Japan, Southeast Asia, Latin America, Europe, and the Middle East.

Core Business Segments

  • Prescription Drugs: Treatments for infections (gram-positive/negative organisms, vancomycin-resistant enterococcus faecium), respiratory conditions (acute bacterial sinusitis, bronchitis, pneumonia), anemia, diabetes, hypertension, GERD, and cancers (pleural mesothelioma, non-small cell lung cancer, colorectal cancer).
  • Health & Beverage Products: Hangover relief drinks, ready-to-drink supplements, health functional foods, and active pharmaceutical ingredients.
  • Beauty Solutions: Brands like bewants, ScalpMed, and KLEDERMA RX offering specialized skincare and haircare products.

Global Reach

The company exports its innovative pharmaceutical and consumer health products to multiple regions, ensuring accessibility to diverse markets.

Frequently Asked Questions

  • What is HK inno.N's (KOSDAQ-195940) current market cap?
    As of 06/18/2025, HK inno.N (including the parent company, if applicable) has an estimated market capitalization of $873.58 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • HK inno.N global market capitalization ranking is approximately 10199 as of 06/18/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.